Navigation Links
Aspreva receives Investment Canada approval for acquisition by Galenica
Date:12/21/2007

to, statements about: the potential acquisition of Aspreva by Galenica in an all cash transaction valued at USD$26.00 per outstanding share (the "Acquisition"); the remaining conditions to the closing being satisfied or waived; and the expected closing of the Acquisition on January 3, 2008.

With respect to the forward-looking statements contained in this news release, Aspreva has made numerous assumptions regarding, among other things: Galenica's ability to finance the Acquisition valued at USD$26.00 per outstanding share; the ability of Aspreva and Galenica to satisfy all of the closing conditions to complete the Acquisition; Aspreva's ability to protect its intellectual property rights and to not infringe on the intellectual property rights of others; and Aspreva's ability to comply with applicable governmental regulations and standards. Readers are cautioned that the plans, intentions or expectations disclosed in any forward-looking statements and underlying assumptions may not be achieved and that they should not place undue reliance on any forward-looking statement. Actual results or events could differ materially from the plans, intentions, expectations, and assumptions expressed or implied in any forward-looking statements as a result of numerous risks, uncertainties and other factors, including those relating to: the possibility of not satisfying all of the closing conditions to complete the Acquisition; risks related to integration of acquisitions; competition from other pharmaceutical or biotechnology companies; economic and capital market conditions; and currency exchange rates.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Ca
'/>"/>

SOURCE Aspreva Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Aspreva to Announce 2007 Third Quarter Results on October 31st
2. Aspreva Announces Preliminary Revenues for Third Quarter 2007
3. Aspreva to be Acquired by Galenica For US$915 Million
4. Aspreva Sends Materials for Special Meeting to be Held December 17
5. Aspreva obtains shareholder approval for acquisition by Galenica
6. Aspreva receives final court approval for acquisition by Galenica
7. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
8. DaVita Receives Civil Complaint
9. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
10. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
11. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and ... the drug delivery partnering deals and agreements entered into ... report provides a detailed understanding and analysis of how ... majority of deals are discovery or development stage whereby ... to license the license drug delivery technology. These deals ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Parker ... protecting the rights of victims injured by defective medical ... review of Medtronic’s Infuse bone graft products are now ... a medical journal, the two studies serve up two ... effectiveness” when comparing Infuse and the traditional bone graft; ...
(Date:6/18/2013)... ENT and Allergy Associates, LLP (ENTA) does not ... , New York/New Jersey’s premier ear, nose, throat, ... offering superior healthcare to children and adults in hundreds ... York area-only considers adding to its current footprint when ... the right communities to serve, the right locations from ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3
... between micronutrient supplementation and reduced risk of recurrence during ... June 1 issue of The Journal of Infectious Diseases, ... tuberculosis therapy, once common before the advent of anti-TB ... therapy in most low-income countries even though poor nutrition ...
... Johnson &,Johnson will participate in the Morgan Stanley ... The Ritz-Carlton in Key Biscayne,Florida. Dominic Caruso, Vice ... Company in a session scheduled at 2:20 p.m.,(Eastern ... investors and other interested parties,by accessing the Johnson ...
... that are helping doctors diagnose and treat lung ... Lung Cancer Conference jointly organized by the European ... Association for the Study of Lung Cancer (IASLC) ... No. 81O; Friday 25th April, 16:30), Israeli researchers ...
... autism are increasingly turning to sensory integration treatment ... and theyre seeing good results. In 2007, 71 ... treatment used sensory integration methods, and 91 percent ... from Temple University researchers, presented this month at ...
... (NYSE: HRC ) fiscal 2008 second quarter earnings ... invited to view its webcast the,following morning on Wednesday, ... Release: Hill-Rom Holdings, Inc.,s Fiscal 2008 Second Quarter,Earnings Release ... released to,the public after the NYSE close on Tuesday, ...
... in OTC Private Label Market, PRINCETON, N.J., ... owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced,today ... U.S. Food and Drug,Administration to manufacture and market ... Oral Solution,(Hives-Relief), 1 mg/mL (OTC). The Office of ...
Cached Medicine News:Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2Health News:New genetic techniques to combat lung cancer 2Health News:Autistic mannerisms reduced by sensory treatment 2Health News:Autistic mannerisms reduced by sensory treatment 3Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast 2Health News:Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution 2
(Date:6/18/2013)... 18, 2013 Apama Medical, a privately ... of next-generation atrial fibrillation technologies, today announced the ... US Patent and Trademark Office (USPTO), titled "Low ... assemblies for use on expandable structures such as ... procedures. "We are grateful to the ...
(Date:6/18/2013)... Calif. , June 18, 2013  Isis Pharmaceuticals, Inc. ... today announced that management will present a general corporate update ... Open House on Tuesday, June 25 at 2:10 p.m. Pacific ... The agenda for the meeting is as follows: 2:00 p.m. ... of record as of April 26, 2013) 2:10 p.m. – ...
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Lenses: The Bausch & Lomb PMMA Posterior Chamber ... primary implantation for the visual correction of aphakia ... where a cataractous lens has been removed by ... be placed in the ciliary sulcus or capsular ...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: